Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma

This phase I study evaluated the safety and efficacy of single-agent ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (aged 20-69 years and ineligible for chemotherapy using fludarabine or cyclophosphamide, or aged ≥70 years). Eight pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Shibayama, Hirohiko, Teshima, Takanori, Choi, Ilseung, Hatake, Kiyohiko, Sekiguchi, Naohiro, Yoshinari, Nozomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JSLRT 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954169/
https://www.ncbi.nlm.nih.gov/pubmed/31866619
http://dx.doi.org/10.3960/jslrt.19023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954169/
https://www.ncbi.nlm.nih.gov/pubmed/31866619
http://dx.doi.org/10.3960/jslrt.19023

Ejemplares similares